Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

Sunnia T. Chen(The Ohio State University Wexner Medical Center), Daniel Addison(The Ohio State University Wexner Medical Center), Lindsay Rosen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Tracy Wiczer(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer A. Woyach(The Ohio State University), John Alan Gambril(The Ohio State University Wexner Medical Center), Patrick Ruz(The Ohio State University Wexner Medical Center), Kerry A. Rogers(The Ohio State University), Sujay Kalathoor(The Ohio State University Wexner Medical Center), Seema A. Bhat(The Ohio State University), Michael R. Grever(Johns Hopkins University), Leylah Azali(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Farrukh T. Awan(The Ohio State University), Adam S. Kittai(The Ohio State University Wexner Medical Center), Qiuhong Zhao(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John C. Byrd(The Ohio State University), Marilly Palettas(The Ohio State University), Onaopepo Kola‐Kehinde(The Ohio State University Wexner Medical Center)
Journal of Hematology & Oncology
July 14, 2022
Cited by 36


Related Papers